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Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. It mostly occurs in older age
groups (usually those 50 to 60 years old), and rarely in young adults. The survival rate of these young HCC patients
is usually very low. The authors report a case of a 22-year old man with diffuse-type HCC who successfully achieved
complete remission for 46 months after second transcatheter arterial chemoembolization using gelatin sponge
particles (Eric Kang Pharmaceutical Technology Co., Ltd. Hangzhou, China) combined with pirarubicin.
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Hepatocellular carcinoma (HCC) is a common malig-
nancy worldwide, especially in South East Asia and Africa
[1] and is the most common primary tumor of the liver
[2,3]. Hepatocellular carcinoma can be classified into three
types based on gross morphological characteristics: no-
dular, massive, or diffuse [4]. Although the nodular and
massive types constitute the majority of HCC lesions,
diffuse-type HCC still accounts for 7 to 13% of cases
[5,6]. Worldwide, HCC mostly occurs in older age groups
(usually 50 to 60 years old), and rarely in young adults [7].
However, the age distribution of patients with HCC dif-
fers substantially in different parts of the world. In Africa,
HCC often affects young people, with 40% of those af-
flicted being under the age of 30 [8]. In China, it is rela-
tively rare for people under 35 years old to have HCC.
The survival rate of these young HCC patients is usually
very low [9]. Compared with adult HCC, morphologically
the tumor is often massive, diffused, with quicker growth,
stronger invasiveness, and poor prognosis [10]. Diffuse-
type HCC almost always presents an advanced infiltrative
tumor, so surgery is rarely indicated; rather, locore-
gional therapy in the form of transcatheter arterial* Correspondence: zhangyuewei1121@163.com
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therapeutic option [11].
In this case, we performed TACE using gelatin sponge
particles (GSPs) to treat a 22-year-old patient with diffuse-
type hepatocellular carcinoma, and achieved complete re-
mission. At the most recent follow-up, our patient had
complete remission for 46 months after the second treat-
ment, without any clinical disease recurrence.
Case presentation
A 22-year old male patient presented at our hospital
with a 3-month history of acute onset of abdominal pain
in July 2009. Contrast-enhanced abdominal magnetic
resonance imaging (MRI) revealed more than 100 liver
lesions, with the largest having a diameter of about
1.55 cm (Figure 1a). Laboratory results revealed a total
bilirubin level of 26 μmol/l, albumin level of 51 g/l, ala-
nine transaminase level of 38 IU/l and α-fetoprotein
(AFP) level of 4,773 ng/ml. The patient had a history
of chronic hepatitis B infection for 4 years. The clini-
cal diagnosis was hepatocellular carcinoma (diffuse-type).
The status of the patient was graded as Child-Pugh
class A, with an Eastern Cooperative Oncology Group
(ECOG) Performance Status of 0, and was classified by
the Barcelona Clinic Liver Cancer (BCLC) system as
stage B. Curative treatments, such as surgery or radiofre-
quency ablation, were not possible, owing to the extent ofs is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Abdominal computed tomography (CT) or magnetic resonance imaging (MRI). (a) Abdominal dynamic enhanced MRI obtained
before treatment shows multiple liver lesions, the number of nodules >100, the largest diameter was about 1.55 cm; AFP level, 4,773 ng/ml.
(b) CT scan obtained 2 months after the start of treatment showed that the lesion was not enhanced in the arterial phase; AFP level, 3.79 ng/ml.
(c) CT scan obtained 15 months after the start of treatment showed that the number of low-density lesions was less than before, also no
enhancement; AFP level, 3.63 ng/ml. (d) CT scan obtained 21 months after the start of treatment showed that the diffuse liver lesions disappeared,
no abnormal enhancement lesions; AFP level, 2.26 ng/ml. (e) MRI scan obtained 46 months after the second treatment showed that there were still
no lesions in the liver; AFP, level 3.73 ng/ml.
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GSPs (350 to 560 μm in diameter) mixed with chemother-
apeutic agent pirarubicin, 10 mg). As the nodules were
scattered throughout the liver, we performed complete
embolization of both hepatic arteries (Figure 2b). One
month later, contrast-enhanced abdominal computed to-
mography (CT) showed significant necrosis of the tumor,
mostly without any enhancement in the arterial phase.
The patient’s AFP level decreased to 34.4 ng/ml. Once
again, TACE was performed with a supersolution of
30 mg GSPs and 10 mg pirarubicin. One month later,
contrast-enhanced CT showed no enhancement in the
arterial phase (Figure 1b). The patient’s AFP level was
3.79 ng/ml. Since then, AFP levels obtained from testing
every one to two months, have been within the normal
range (Figure 3). In addition, contrast-enhanced CT was
also performed every 3 to 6 months, and showed that
the lesions gradually reduced or disappeared with no new
local tumor formation. During this period, the patient hasbeen taking antiviral drugs (Lamivudine, 100 mg once
daily). At July 2013, the patient had been in complete
remission for 46 months according to the modified Re-
sponse Evaluation Criteria in Solid Tumors (RECIST).
Discussion
In China, HCC is rare in young adults and mostly occurs
in men. In particular, diffuse-type HCC, when presented
by young adults, has a typical clinical manifestation that
includes high malignancy, lack of early diagnosis and
poor prognosis [10,12]. In accordance with the BCLC
clinical staging and treatment system [13], surgical resec-
tion is considered to be the primary treatment method. It
is more suitable for patients with a single lesion of diam-
eter less than 5 cm, and normal total bilirubin levels with-
out portal hypertension. Radiofrequency ablation is more
limited to <3 localized lesions, with tumors ≤3 cm in
diameter [14]. Liver transplantation is also considered as
one of the curative methods; especially applicable to the
Figure 2 Hepatic artery angiography. (a) Hepatic arteriogram shows infiltrative tumor staining in the whole hepatic lobe. Transarterial
chemoembolization was performed with a mixture of 30 mg GSPs and 10 mg pirarubicin. (b) After GSP embolization, digital subtraction
angiography showed that the feeding artery of the tumor was completely blocked. (c) 1 month later, a follow-up angiogram shows almost
complete disappearance of tumor vascularity. (d) A second and final GSP-TACE was performed. After that, the feeding artery of the tumor was
completely blocked again.
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thods or where there is no improvement in the patient’s
condition [15]. It is also limited to localized lesions, single
tumors with diameter less than 5 cm or multiple tumors
numbering less than three tumors in total with diame-
ters ≤3 cm, according to Milan criteria [16]. Transcatheter
arterial chemoembolization with lipiodol (lipiodol-TACE)
is the standard treatment for unresectable intermediate-
stage HCC. However, different studies have shown an
overall response rate of 17% to 61.9% and a complete
tumor necrosis rate of only 0 to 4.8% [17-19].
The DC bead is an embolic drug-eluting bead that is
used in the treatment of patients with both primary andFigure 3 Change in AFP levels. When disease was found, the AFP
level was 4,773 ng/ml. After the first treatment, the AFP level
decreased to 34.4 ng/ml. The AFP level began to drop to normal
after the second TACE. Since then, AFP levels have been within the
normal range, as reviewed every 1 to 2 months.secondary liver cancers [20]. Compared with lipiodol-
TACE, using this embolization agent to perform TACE
can gain higher tumor necrosis and lower postoperative
complications [21]. However, DC beads are not available
in China. This patient’s cancer was not suitable for the use
of permanent embolic agents, such as polyvinyl acetate or
DC beads, as these require superselective embolization.
The size of the lesions in this patient was <3 cm, and the
lesions involved the whole liver. Transcatheter arterial in-
fusion is the only suitable option for such patients. How-
ever, we chose GSPs as an alternative particulate embolic
agent. The particle diameter is more suitable for use in
blood vessels, and better suits the objective of delivering
an embolic agent to block tumor target vessels regionally.
As GSPs are absorbable particles that dissolve over time,
the blocked artery can recanalize in about 2 weeks [22],
ensuring the protection of postoperative liver function. In
our recent study, we use GSPs to deal with a massive type
of HCC, leading to a good efficacy and safety [23].
Conclusions
In this case, the patient was a young 22-year-old man in
whom liver MRI suggested multiple grain-size lesions
(>100 nodules). Obviously, he was not a candidate for sur-
gical resection and radiofrequency ablation, nor was liver
transplantation indicated, according to the Milan criteria.
However, how to acquire effective intervention and long-
term survival is a clinical problem. We performed TACE
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were no signs of acute liver failure and the liver function
returned to normal after 7 days. The AFP level decreased
to normal after the second TACE procedure. To date, the
patient has been in complete remission for 46 months.
The young man has just married, living a beatific life.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the editor-in-chief of this journal.
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